287 related articles for article (PubMed ID: 20347974)
21. Aiming for a moving target: challenges with impactor measurements of MDI aerosols.
Stein SW
Int J Pharm; 2008 May; 355(1-2):53-61. PubMed ID: 18191510
[TBL] [Abstract][Full Text] [Related]
22. Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. extension of archival calibration to 15 L/min.
Marple VA; Olson BA; Santhanakrishnan K; Roberts DL; Mitchell JP; Hudson-Curtis BL
J Aerosol Med; 2004; 17(4):335-43. PubMed ID: 15699634
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the need to coat particle collection cups of the NGI to mitigate droplet bounce when evaluating nebuliser-produced droplets.
Berg E; Lamb P; Ali A; Dennis J; Tservistas M; Mitchell J
Pharmeur Sci Notes; 2008 Feb; 2008(1):21-5. PubMed ID: 18430403
[TBL] [Abstract][Full Text] [Related]
24. Size analysis of a pressurized metered dose inhaler-delivered solution formulation by an Aerosizer-LD time-of-flight aerosol particle size spectrometer.
Nagel MW; Wiersema KJ; Bates SL; Mitchell JP
J Aerosol Med; 2002; 15(1):75-85. PubMed ID: 12006148
[TBL] [Abstract][Full Text] [Related]
25. [Aerosol therapy].
Wildhaber JH
Schweiz Med Wochenschr; 1998 Aug; 128(33):1223-8. PubMed ID: 9757487
[TBL] [Abstract][Full Text] [Related]
26. The abbreviated impactor measurement (AIM) concept: part II--Influence of evaporation of a volatile component-evaluation with a "droplet-producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent.
Mitchell JP; Nagel MW; Avvakoumova V; MacKay H; Ali R
AAPS PharmSciTech; 2009; 10(1):252-7. PubMed ID: 19291411
[TBL] [Abstract][Full Text] [Related]
27. Measurement of the Raman spectra and hygroscopicity of four pharmaceutical aerosols as they travel from pressurised metered dose inhalers (pMDI) to a model lung.
Davidson N; Tong HJ; Kalberer M; Seville PC; Ward AD; Kuimova MK; Pope FD
Int J Pharm; 2017 Mar; 520(1-2):59-69. PubMed ID: 28159683
[TBL] [Abstract][Full Text] [Related]
28. Time-of-flight aerodynamic particle size analyzers: their use and limitations for the evaluation of medical aerosols.
Mitchell JP; Nagel MW
J Aerosol Med; 1999; 12(4):217-40. PubMed ID: 10724637
[TBL] [Abstract][Full Text] [Related]
29. Application of heated inlet extensions to the TSI 3306/3321 system: comparison with the Andersen cascade impactor and next generation impactor.
Myrdal PB; Mogalian E; Mitchell J; Nagel M; Wright C; Kiser B; Prell M; Woessner M; Stein SW
J Aerosol Med; 2006; 19(4):543-54. PubMed ID: 17196082
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Abbreviated Impactor Measurements (AIM) and Efficient Data Analysis (EDA) for Dry Powder Inhalers (DPIs) Against the Full-Resolution Next Generation Impactor (NGI).
Mohan M; Lee S; Guo C; Peri SP; Doub WH
AAPS PharmSciTech; 2017 Jul; 18(5):1585-1594. PubMed ID: 27624069
[TBL] [Abstract][Full Text] [Related]
31. The on-line analysis of aerosol-delivered pharmaceuticals via single particle aerosol mass spectrometry.
Morrical BD; Balaxi M; Fergenson D
Int J Pharm; 2015 Jul; 489(1-2):11-7. PubMed ID: 25891255
[TBL] [Abstract][Full Text] [Related]
32. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations.
Pilcer G; Vanderbist F; Amighi K
Int J Pharm; 2008 Jun; 358(1-2):75-81. PubMed ID: 18359587
[TBL] [Abstract][Full Text] [Related]
33. Comparison of delivery characteristics from a combination metered-dose inhaler using the Andersen cascade impactor and the next generation pharmaceutical impactor.
Guo C; Gillespie SR; Kauffman J; Doub WH
J Pharm Sci; 2008 Aug; 97(8):3321-34. PubMed ID: 17932959
[TBL] [Abstract][Full Text] [Related]
34. Size distribution of chromate paint aerosol generated in a bench-scale spray booth.
Sabty-Daily RA; Hinds WC; Froines JR
Ann Occup Hyg; 2005 Jan; 49(1):33-45. PubMed ID: 15596421
[TBL] [Abstract][Full Text] [Related]
35. A novel method of characterizing medicinal drug aerosols generated from pulmonary drug delivery devices.
Ali M
PDA J Pharm Sci Technol; 2010; 64(4):364-72. PubMed ID: 21502037
[TBL] [Abstract][Full Text] [Related]
36. Size and concentration measurement of an industrial aerosol.
O'Brien D; Baron P; Willeke K
Am Ind Hyg Assoc J; 1986 Jul; 47(7):386-92. PubMed ID: 3751888
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the Malvern Spraytec with inhalation cell for the measurement of particle size distribution from metered dose inhalers.
Haynes A; Shaik MS; Krarup H; Singh M
J Pharm Sci; 2004 Feb; 93(2):349-63. PubMed ID: 14705192
[TBL] [Abstract][Full Text] [Related]
38. Impact of droplet evaporation rate on resulting in vitro performance parameters of pressurized metered dose inhalers.
Sheth P; Grimes MR; Stein SW; Myrdal PB
Int J Pharm; 2017 Aug; 528(1-2):360-371. PubMed ID: 28599855
[TBL] [Abstract][Full Text] [Related]
39. The influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon-free propellant-driven metered dose inhalers.
Smyth HD; Beck VP; Williams D; Hickey AJ
AAPS PharmSciTech; 2004 Feb; 5(1):E7. PubMed ID: 15198528
[TBL] [Abstract][Full Text] [Related]
40. In vitro aerosol characterization of Staccato(®) Loxapine.
Dinh K; Myers DJ; Glazer M; Shmidt T; Devereaux C; Simis K; Noymer PD; He M; Choosakul C; Chen Q; Cassella JV
Int J Pharm; 2011 Jan; 403(1-2):101-8. PubMed ID: 20971174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
